Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Outlines Next Steps For Online Repository And Standard Elements For Device Labeling

This article was originally published in The Gray Sheet

Executive Summary

Industry representatives, health care providers, patients and caregivers gathered April 29-30 to discuss CDRH labeling activities and the agency’s ideas for the future.

Advertisement

Related Content

Standardized Device Labeling? CDRH Studies Practitioner Perceptions
Home-Use E-Labeling Pilot Round 2: CDRH Seeks Volunteers
Standardized Device Labeling? CDRH Studies Practitioner Perceptions
FDA’s Device Labeling Proposed Rule Misses The Mark, Industry Says
An Online Labeling Repository? Device Firms Are Lukewarm At Best
FDA Proposes Rule On Symbols In Device Labeling
FDA Says Pilot On Standard Electronic Labeling For Devices “Didn’t Work”
FDA To Survey Clinicians About Adding “Highlights” Section To Device Labeling
Companies Worry About Cost Of FDA's Device Labeling Database

Topics

Advertisement
UsernamePublicRestriction

Register

MT032011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel